{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triptorelin+Pamoate",
    "query": {
      "intervention": "Triptorelin Pamoate"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 46,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Triptorelin+Pamoate&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T12:06:18.089Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04557059",
      "title": "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "LHRHa",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Janssen Pharmaceutica N.V., Belgium",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 691,
      "start_date": "2020-11-12",
      "completion_date": "2031-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-03T12:06:18.089Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Jeffersonville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04557059"
    },
    {
      "nct_id": "NCT03809000",
      "title": "A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "GnRH analog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "RTOG Foundation, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 188,
      "start_date": "2019-04-15",
      "completion_date": "2029-09-15",
      "has_results": true,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-09-03T12:06:18.089Z",
      "location_count": 106,
      "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03809000"
    },
    {
      "nct_id": "NCT00567580",
      "title": "Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "PBRT",
          "type": "RADIATION"
        },
        {
          "name": "PLNRT",
          "type": "RADIATION"
        },
        {
          "name": "AA",
          "type": "DRUG"
        },
        {
          "name": "LHRH agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1792,
      "start_date": "2008-02",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2025-05-09",
      "last_synced_at": "2026-09-03T12:06:18.089Z",
      "location_count": 444,
      "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00567580"
    },
    {
      "nct_id": "NCT01492972",
      "title": "Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Androgen Suppression Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Proton Collaborative Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 192,
      "start_date": "2012-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-09-03T12:06:18.089Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Warrenville, Illinois • Oklahoma City, Oklahoma + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Warrenville",
          "state": "Illinois"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Hampton",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01492972"
    },
    {
      "nct_id": "NCT05498272",
      "title": "Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "BRCA1 Mutation",
        "BRCA2 Mutation",
        "Prostatic Adenocarcinoma",
        "High-Risk Cancer"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "LHRH agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rana McKay, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2023-02-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-03T12:06:18.089Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Baltimore, Maryland • New York, New York + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05498272"
    },
    {
      "nct_id": "NCT04484818",
      "title": "Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Triptorelin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2021-03-01",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-03T12:06:18.089Z",
      "location_count": 115,
      "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 88 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04484818"
    },
    {
      "nct_id": "NCT00066703",
      "title": "Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "exemestane",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "triptorelin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ETOP IBCSG Partners Foundation",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 2672,
      "start_date": "2003-11-03",
      "completion_date": "2024-10-23",
      "has_results": true,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-09-03T12:06:18.089Z",
      "location_count": 139,
      "location_summary": "Burbank, California • La Jolla, California • Mission Hills, California + 106 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00066703"
    },
    {
      "nct_id": "NCT01790126",
      "title": "The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ARN-509",
          "type": "DRUG"
        },
        {
          "name": "LHRH Agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aragon Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 90,
      "start_date": "2013-03-04",
      "completion_date": "2019-03-01",
      "has_results": true,
      "last_update_posted_date": "2020-03-11",
      "last_synced_at": "2026-09-03T12:06:18.089Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01790126"
    },
    {
      "nct_id": "NCT05189457",
      "title": "First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Luteinizing Hormone Releasing Hormone",
          "type": "DRUG"
        },
        {
          "name": "New Hormonal Agent",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2022-01-25",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-09-03T12:06:18.089Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05189457"
    },
    {
      "nct_id": "NCT02278185",
      "title": "Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Recurrent Prostate Cancer",
        "Stage III Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "goserelin acetate",
          "type": "DRUG"
        },
        {
          "name": "histrelin acetate",
          "type": "DRUG"
        },
        {
          "name": "triptorelin",
          "type": "DRUG"
        },
        {
          "name": "degarelix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "19 Years and older · Male only"
      },
      "enrollment_count": 19,
      "start_date": "2015-11-11",
      "completion_date": "2024-07-18",
      "has_results": true,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-09-03T12:06:18.089Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Fort Collins, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02278185"
    }
  ]
}